Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 9/20 | 0.34 |
| ▸ | GRM5 | P41594 | 7/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986371 | 1.00 | GRM1 (0.34) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL986695 | 0.89 | NAMPT (0.41) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL988378 | 0.85 | ERN1 (0.40) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL984594 | 0.85 | ERN1 (0.37) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL985675 | 0.84 | CCNT1 (0.37) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL984990 | 0.84 | NAMPT (0.38) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL982882 | 0.84 | GRM1 (0.49) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL987228 | 0.84 | KCNN4 (0.35) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL982752 | 0.83 | GRM1 (0.39) | GRM1GRM5HRH1TMEM97CCNT1 | |
| SCHEMBL13593423 | 0.83 | CDK9 (0.33) | GRM1GRM5CCNT1CDK9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | GRM1 1117/4885GRM5 1526/4885HRH1 2201/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | GRM1 1117/4885GRM5 1526/4885HRH1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.